Document Classification

Section Type: RESULTS

Text: In the placebo arm, homozygotes (6. 3 % of study population) had a significantly increased risk of fatal coronary disease or nonfatal myocardial infarction (D/MI) compared with noncarriers (OR 2. 12, 95 % CI 1. 07 to 4. 19, P = 0. 03), and in the entire study the benefit of pravastatin in reducing the risk of D/MI was greater in these subjects (OR 0. 21, 95 % CI 0. 06 to 0. 69) than in heterozygotes (OR 0. 74, 95 % CI 0. 48 to 1. 14) or noncarriers (OR 0. 99, 95 % CI 0. 68 to 1. 42 ; P (interaction) = 0. 044).